- Home
- BBD vs IQV Comparison
BBD vs IQV Comparison
Compare BBD & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BBD | IQV |
|---|---|---|
| Founded | 1943 | 1982 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.6B | 36.4B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | BBD | IQV |
|---|---|---|
| Price | $3.33 | $225.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 17 |
| Target Price | $2.55 | ★ $237.59 |
| AVG Volume (30 Days) | ★ 36.5M | 1.4M |
| Earning Date | 10-29-2025 | 10-28-2025 |
| Dividend Yield | ★ 5.01% | N/A |
| EPS Growth | ★ 47.11 | N/A |
| EPS | 0.38 | ★ 7.30 |
| Revenue | ★ $16,507,289,161.00 | $15,904,000,000.00 |
| Revenue This Year | $78.26 | $6.14 |
| Revenue Next Year | $7.53 | $5.35 |
| P/E Ratio | ★ $8.93 | $30.81 |
| Revenue Growth | ★ 16.68 | 3.85 |
| 52 Week Low | $1.84 | $134.65 |
| 52 Week High | $3.77 | $234.30 |
Technical Indicators
Market Signals| Indicator | BBD | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 39.06 | 57.52 |
| Support Level | $3.55 | $214.01 |
| Resistance Level | $3.73 | $230.80 |
| Average True Range (ATR) | 0.10 | 5.87 |
| MACD | -0.03 | -0.49 |
| Stochastic Oscillator | 1.19 | 55.80 |
Price Performance
Historical ComparisonAbout BBD Banco Bradesco Sa
Banco Bradesco is Brazil's second-largest private bank, with about 10%-15% of deposits, and the largest insurance provider in Brazil, with roughly 20%-25% market share. The bank is majority controlled by the Bradesco foundation—a private nonprofit institution focused on education. The bank is also a major asset manager with high-single-digit market share. In 2016, Bradesco acquired the Brazilian operations of HSBC.
About IQV IQVIA Holdings Inc.
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.